Table 1 Participant demographics

From: Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer’s disease

 

Cases (Aβ PET+) n = 15

Controls (Aβ PET−) n = 20

p value

Effect size

95% CI

Age*

68.5 ± 8.1

69.1 ± 2.7

0.77

0.57

−3.35–4.48

Sex (female/male)†

13/2

13/7

0.15

0.29

0.05–1.64

Lens (phakic/pseudophakic)†

12/3

19/1

0.17

0.21

0.02–2.27

Macular drusen (yes/no)†

3/12

5/15

0.73

1.33

0.26–6.74

Peripheral drusen (yes/no)†

3/12

5/15

0.73

1.33

0.26–6.74

Glaucoma (yes/no)†

1/14

2/18

0.73

1.56

0.13–18.96

RNFL thickness (μm)*

97.5 ± 12.7

92.9 ± 12.7

0.29

−4.68

−13.50–4.13

MMSE*

23.2 ± 3.5

27.8 ± 1.6

<0.0001

4.6

2.8–6.4

  1. PET positron emission tomography, RNFL retinal nerve fibre layer, MMSE mini mental state examination
  2. *Continuous variables are expressed as mean ± standard deviation and analysed with an unpaired two-tailed t test. The effect size and corresponding 95% CI are that of the difference between means.
  3. †Dichotomous variables are expressed as number of participants and analysed with chi-square test. The effect size and corresponding 95% CI are those of the odds ratio
Back to article page